Self-Medication with Ganoderma lucidum ('Reishi') to Combat Parkinson's Disease Symptoms
| Autor: | Kim P. C. Kuypers |
|---|---|
| Přispěvatelé: | RS: FPN NPPP II, Section Psychopharmacology |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Parkinson's disease Reishi STRESS Medicine (miscellaneous) Ganoderma lucidum • Disease Motor symptoms VALIDATION s disease 03 medical and health sciences case report • 0302 clinical medicine Internal medicine LINGZHI Medicine Self-medication VALIDITY COMPASSION SCALE Ganoderma lucidum 030109 nutrition & dietetics Nutrition and Dietetics business.industry Parkinson&apos ADULTS EMOTION REGULATION medicine.disease 030220 oncology & carcinogenesis business DIFFICULTIES |
| Zdroj: | Journal of Medicinal Food, 24(7), 766-773. Mary Ann Liebert Inc. |
| ISSN: | 1096-620X |
| DOI: | 10.1089/jmf.2020.0137 |
| Popis: | Parkinson's disease (PD) is a prevalent neurodegenerative disease for which only symptomatic treatments, mainly focused on motor symptoms. In contrast, conventional pharmacological treatments do not address cognitive impairment and emotional dysfunction. Together with potential treatment side effects, these can cause distress, lower the quality of life, and increase motor impairment in patients. Preclinical research suggests that the Traditional Chinese Medicine Ganoderma lucidum (“Reishi”) can alleviate symptoms in neurological disorders like PD. However, no clinical research to date has addressed this. An (unmedicated) patient, 50 years of age and diagnosed with PD for 5 years, approached the author as he decided to initiate self-treatment with Reishi, lasting 3 months. He wanted to evaluate the effects and decide to continue self-treatment or not. He agreed to be followed during this period, using questionnaires asking him about his (non-)motor symptoms. The most notable finding was the increase in Mindfulness, 3 months after self-treatment started. The motor symptoms stayed stable, there were no extreme changes in quality of life, and emotion regulation seemed to deteriorate over time while slightly improving at the 3-month assessment. While the findings do not allow firm conclusions seen the nature (N = 1) of this study, the small positive changes in some facets of affective behavior and the patient's experience, combined with the evidence from preclinical research, warrant clinical studies in this patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|